{"id":1022270,"date":"2026-11-18T09:56:02","date_gmt":"2026-11-18T14:56:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/"},"modified":"2026-11-18T09:56:02","modified_gmt":"2026-11-18T14:56:02","slug":"hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/","title":{"rendered":"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health<\/b><\/p>\n<p class=\"bwalignc\"><i>A new specialty built to support each person\u2019s unique, ever-changing biology, with real medical leadership at every step<\/i><\/p>\n<p>SAN FRANCISCO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nHims &amp; Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC-157 and TB-500 will follow, consistent with regulatory standards.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20261118064284\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261118064284\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/2974788\/4\/26Q4_HH-peptides_businesswire.jpg\" alt=\"\" \/><\/div>\n<p>\nUntil now, getting these types of medications has often meant relying on unreliable and unregulated online sellers, or a high-cost longevity clinic. Peptides+ offers customers more accessible care, backed by real medical leadership and with consistent clinical oversight, because optimizing health shouldn\u2019t be a privilege of the few.<\/p>\n<p>\nEvery plan starts with a comprehensive intake of health history and goals, so a licensed provider trained in peptide therapies can assess each individual and, if appropriate, tailor a personalized protocol to their needs. Treatments are compounded in the U.S. and dispensed directly by licensed, U.S. pharmacies regulated by state boards of pharmacy and held to rigorous quality and safety standards. The care team follows up regularly and can adjust the plan as needed, because what someone needs now may not be what they need in a year, or in ten years.<\/p>\n<p>\n\u201cPeptides+ gives men a clinically guided, personalized plan built around their goals, backed by a licensed provider who understands these therapies,\u201d said Anant Vinjamoori, MD, MBA, Chief Medical Officer of Hims. \u201cAnyone investing in their health deserves to know exactly what they\u2019re putting in their body, and to have dedicated support along the way.\u201d<\/p>\n<p>\n\u201cWomen are used to being told their fatigue, brain fog, and changing bodies are simply part of life, and many have had to advocate for themselves just to be heard,\u201d said Jessica Shepherd, MD, MBA, FACOG, Chief Medical Officer of Hers. \u201cWe believe women deserve a more comprehensive and personalized approach to their health, one that considers their unique health history, evolving needs and individual goals. The emerging therapies in Peptides+ have exciting potential. Meaningful outcomes start with understanding the whole person, making informed, evidence-based decisions and ensuring women have trusted medical guidance and ongoing support at every stage of life.\u201d<\/p>\n<p>\nPeptides are short chains of amino acids that act as the body\u2019s own signaling molecules, telling cells what to do, from energy and recovery to metabolism and focus. Peptide therapies aren\u2019t new to medicine: for instance, insulin is a well-understood and well-established peptide therapy. What\u2019s new is making it seamless to access these emerging peptides alongside clinical expertise.<\/p>\n<p>\nFive U.S.-compounded treatments in the Peptides+ specialty are available at launch:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Sermorelin<\/b> is a peptide that supports the body\u2019s own growth hormone signaling, which plays a role in muscle, metabolism, and recovery.\n<\/li>\n<li><b>NAD+<\/b> is a coenzyme that helps cells produce energy and repair DNA. Natural levels tend to decline with age.\n<\/li>\n<li><b>Glutathione<\/b> is a naturally occurring antioxidant that supports the body\u2019s cellular defenses against oxidative stress.\n<\/li>\n<li><b>Vitamin B12<\/b> supports energy production, red blood cell formation, and brain and nervous system health. Low levels can cause fatigue, weakness, and brain fog in people who are deficient.\n<\/li>\n<li><b>L-Carnitine<\/b> is made from amino acids and supports cellular energy function and how the body uses fat for fuel.\n<\/li>\n<\/ul>\n<p>\nPeptides+ is available with Care+, which pairs treatment with a comprehensive insights and support experience. Customers receive access to twice a year lab testing to track their progress, unlimited support and ongoing check-ins from a dedicated Care Team, and the option to message providers trained in peptide therapy 24\/7 with any questions. To give customers and their providers a baseline from day one, without an office visit, the Hims Men\u2019s panel includes at-home blood collection and access to lab tests that provide insights across 22 biomarkers, including testosterone, vitamin D, and cholesterol. For those whose lab results indicate potential eligibility, Care+ customers can also connect with a provider to determine if a testosterone treatment may be right for them. The Hers Women\u2019s panel tests 22 biomarkers across hormones, vitamins, and heart health, and marks the first time Hers is offering at-home blood collection for women.<\/p>\n<p>\nToday is just the beginning. Hims &amp; Hers plans to add more peptides and therapies to this specialty, and looks forward to offering BPC-157 and TB-500 consistent with regulatory standards.<\/p>\n<p>\nTo learn more about Peptides+, explore <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hims.com%2Fpeptides-plus&amp;esheet=54643032&amp;newsitemid=20261118064284&amp;lan=en-US&amp;anchor=Hims&amp;index=1&amp;md5=df26956d9ad9d3c027116ef45ad8ebf8\">Hims<\/a> &amp; <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.forhers.com%2Fpeptides-plus&amp;esheet=54643032&amp;newsitemid=20261118064284&amp;lan=en-US&amp;anchor=Hers&amp;index=2&amp;md5=6333ad50e48e5456bc000480789caefd\">Hers<\/a>.<\/p>\n<p><b>About Hims &amp; Hers Health, Inc.<\/b><\/p>\n<p>\nHims &amp; Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That&#8217;s why we&#8217;re building a future where nothing stands in the way of harnessing this power. Hims &amp; Hers normalizes health and wellness challenges\u2014and innovates on their solutions\u2014to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hims.com&amp;esheet=54643032&amp;newsitemid=20261118064284&amp;lan=en-US&amp;anchor=www.hims.com&amp;index=3&amp;md5=66dc694e08e226e6cb24c551bdecfffd\">www.hims.com<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.forhers.com&amp;esheet=54643032&amp;newsitemid=20261118064284&amp;lan=en-US&amp;anchor=www.forhers.com&amp;index=4&amp;md5=d50f848c5efbe441f761727851cad090\">www.forhers.com<\/a>.<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words \u201canticipates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cdecides,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201clikely,\u201d \u201cpotential,\u201d \u201cfuture,\u201d \u201cover time,\u201d \u201ccoming,\u201d \u201chope,\u201d or \u201cshould,\u201d or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the launch and availability of Peptides+, including the treatments available at launch and our plans to add additional peptides and therapies, including BPC-157 and TB-500, consistent with regulatory standards; the availability and expected benefits of Care+ and related lab testing and support offerings; and the potential effects of Peptides+ on our customers and our business. These statements are based on management\u2019s current expectations, but actual results may differ materially due to various factors.<\/p>\n<p>\nForward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to the rollout of Peptides+ and the addition of new peptides and therapies, and the related customer response; the supply chain for the Peptides+ offering; the evolving clinical evidence and regulatory status of the peptide therapies we offer or plan to offer, and our ability to offer such therapies consistent with regulatory standards; other changes in the application, interpretation, and enforcement of healthcare, pharmacy, compounding, consumer protection, or privacy laws or regulations applicable to our business in the United States; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.<\/p>\n<p>\nShould one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of November 18, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261118064284r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261118064284\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261118064284\/en\/<\/a><\/span><\/p>\n<p><b>Press Contact<br \/>\n<\/b><br \/>Susan Cadrecha<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:press@forhims.com\">press@forhims.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Technology Men Retail Health Consumer Vitamins\/Supplements Online Retail Electronic Commerce Pharmaceutical Telemedicine\/Virtual Medicine General Health Internet Fitness &amp; Nutrition Women<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/2974788\/3\/26Q4_HH-peptides_businesswire.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/1851878\/3\/Hims_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health A new specialty built to support each person\u2019s unique, ever-changing biology, with real medical leadership at every step SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211; Hims &amp; Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC-157 and TB-500 will follow, consistent with regulatory standards. This press release features multimedia. View the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1022270","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health A new specialty built to support each person\u2019s unique, ever-changing biology, with real medical leadership at every step SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211; Hims &amp; Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC-157 and TB-500 will follow, consistent with regulatory standards. This press release features multimedia. View the &hellip; Continue reading &quot;Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-18T14:56:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/2974788\/4\/26Q4_HH-peptides_businesswire.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health\",\"datePublished\":\"2026-11-18T14:56:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/\"},\"wordCount\":1545,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20261118064284\\\/en\\\/2974788\\\/4\\\/26Q4_HH-peptides_businesswire.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/\",\"name\":\"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20261118064284\\\/en\\\/2974788\\\/4\\\/26Q4_HH-peptides_businesswire.jpg\",\"datePublished\":\"2026-11-18T14:56:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20261118064284\\\/en\\\/2974788\\\/4\\\/26Q4_HH-peptides_businesswire.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20261118064284\\\/en\\\/2974788\\\/4\\\/26Q4_HH-peptides_businesswire.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/","og_locale":"en_US","og_type":"article","og_title":"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health - Market Newsdesk","og_description":"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health A new specialty built to support each person\u2019s unique, ever-changing biology, with real medical leadership at every step SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211; Hims &amp; Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC-157 and TB-500 will follow, consistent with regulatory standards. This press release features multimedia. View the &hellip; Continue reading \"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-18T14:56:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/2974788\/4\/26Q4_HH-peptides_businesswire.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health","datePublished":"2026-11-18T14:56:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/"},"wordCount":1545,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/2974788\/4\/26Q4_HH-peptides_businesswire.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/","name":"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/2974788\/4\/26Q4_HH-peptides_businesswire.jpg","datePublished":"2026-11-18T14:56:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/2974788\/4\/26Q4_HH-peptides_businesswire.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20261118064284\/en\/2974788\/4\/26Q4_HH-peptides_businesswire.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hims-hers-launches-peptides-a-new-clinically-guided-specialty-for-access-to-personalized-proactive-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022270"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022270\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}